Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement

被引:5
|
作者
Zhang, Wen [1 ]
Xu, Qingwen [1 ]
Peng, Jing [1 ]
Zhang, Xiaotong [1 ]
Chen, Lu [1 ]
Wu, Yilai [1 ]
Yang, Kui [1 ]
Luan, Jiajie [1 ]
Liu, Xiaoyun [1 ]
机构
[1] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Yijishan Hosp, Wuhu, Anhui, Peoples R China
关键词
national centralized drug procurement; medical institutions; problems; challenge; China;
D O I
10.3389/fphar.2023.1233491
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement was investigated and analyzed in order to provide reference for the regulatory agencies to formulate policies.Methods: A questionnaire survey was conducted to collect the problems encountered by 329 Chinese medical institutions in implementing the national centralized drug procurement and the corresponding suggestions provided by relevant experts. Statistical analysis was performed to identify differences in the themes and the number of collected problems, further revealing the relevance to the region in which the medical institutions is located.Result: 1360 problems and suggestions were collected from 329 Chinese medical institutions that located in North (19.15%), Northeast (5.78%), East (33.43%), Central (10.03%), South (9.73%), Southwest (14.89%), and Northwest China (6.99%). There was statistically significant difference in the number of collected problems and suggestions between regions (p < 0.001). Furthermore, the content of gathered problems and suggestions involves in 15 themes including system construction, organizational system and work responsibilities, reasonable measurement and reporting of procurement volume et al. These themes that these medical institutions are focusing on are mainly centered on the supply guarantee (15%), reasonable measurement and reporting of procurement volume (11.40%) and guarantee measures for clinical priority use (9.48%) of drugs with national centralized procurement. Meanwhile, we found that problems regarding the supply guarantee of drugs with national centralized procurement displayed significant difference between regions (p = 0.0096).Conclusion: Chinese medical institutions are facing great challenges in implementing the national centralized drug procurement. The scientific study and judgment of the current situation and the construction of corresponding solution require a precise classification of the problems encountered by medical institutions in the process of implementing the national centralized drug procurement policy, which is of great practical significance for deepening the reform of the medical and health system.
引用
收藏
页数:7
相关论文
共 30 条
  • [1] The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China
    Li, Haoye
    Lin, Fanyu
    Wang, Rui
    Zhu, Chenxuan
    Cao, Keyao
    Chen, Yu
    Fang, Gang
    Li, Jiaming
    Ding, Jinxi
    Li, Wei
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [2] Impact and implications of national centralized drug procurement in China
    Wang, Zhizhou
    Wang, Ke
    Hua, Yiming
    Dong, Xianzhe
    Zhang, Lan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1557 - 1562
  • [3] Influence of Chinese National Centralized Drug Procurement policy on pharmaceutical corporate R&D investment
    Liu, Hang
    Fang, Xinglong
    APPLIED ECONOMICS, 2025, 57 (13) : 1395 - 1414
  • [4] Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
    Wang, Ni
    Yang, Ying
    Xu, Luxinyi
    Mao, Zongfu
    Cui, Dan
    BMC PUBLIC HEALTH, 2021, 21 (01)
  • [5] Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
    Ni Wang
    Ying Yang
    Luxinyi Xu
    Zongfu Mao
    Dan Cui
    BMC Public Health, 21
  • [6] The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
    Chen, Lei
    Yang, Ying
    Luo, Mi
    Hu, Borui
    Yin, Shicheng
    Mao, Zongfu
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (24) : 1 - 11
  • [7] Challenges of sustainable public procurement in Chinese higher education institutions: a Delphi study
    Jin, Xue
    Azam, S. M. Ferdous
    Tham, Jacquline
    JOURNAL OF PUBLIC PROCUREMENT, 2024, 24 (03) : 371 - 392
  • [8] Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
    Zhao, Xinyu
    Li, Min
    Wang, Hao
    Xu, Xiaoqian
    Wu, Xiaoning
    Sun, Yameng
    Ning, Canjian
    Wang, Bingqiong
    Chen, Shuyan
    You, Hong
    Jia, Jidong
    Kong, Yuanyuan
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (03) : 420 - 428
  • [9] Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurement
    Chen, Minxing
    Cong, Lixuan
    He, Jiangjiang
    Yang, Yan
    Xu, Yuan
    Tang, Mi
    Jin, Chunlin
    DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (03): : 145 - 148
  • [10] National centralized drug procurement and health care expenditure of households-micro-evidence from CFPS
    Li, Xin
    Tao, Ran
    Jin, Yuning
    Li, Na
    FRONTIERS IN PUBLIC HEALTH, 2024, 12